Publications

The Ghobrial Lab

Explore the full PubMed publication list

Lightbody ED, Sklavenitis-Pistofidis R, Wu T, Tsuji J, Firer DT, Agius MP, Dutta AK, Barr H, Kim S, Alberge J-B, Nersesian S, Coorens T, Haradhvala NJ, Su NK, Boehner CJ, Aranha MP, Rahmat M, Konishi Y, Hevenor L, Towle K, Horowitz E, Perry J, Davis M, Walsh KA, Cea-Curry CJ, Fleming G, Vinyard ME, Heilpern-Mallory D, El-Khoury H, Cowan A, Ready JE, Marinac CR, Getz G, Ghobrial IM. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature Cancer. 2025.

Alberge JB, Dutta AK, Poletti A, Coorens TH, Lightbody ED, Toenges R, Loinaz X, Wallin S, Dunford A, Priebe O, Dagan J, Boehner CJ, Horowitz E, Su NK, Barr H, Hevenor L, Towle K, Beesam R, Beckwith JB, Perry J, Cordas Dos Santos DM, Bertamini L, Greipp PT, Kubler K, Arndt PF, Terragna C, Zamagni E, Boyle EM, Yong K, Morgan G, Walker BA, Dimopoulos MA, Kastritis E, Hess J, Sklavenitis-Pistofidis R, Stewart C, Getz G, Ghobrial IM. Genomic landscape of multiple myeloma and its precursor conditions. Nature Genetics. 2025.

Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Alberge JB, Aranha MP, Heilpern-Mallory DL, Roweth HG, Huyng D, Chong SJF, Chung AY, Zhang J, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Belkin S, Dutta AK, Knudson RA, Brandt C, Greipp PT, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S. Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q. Blood. 2025.

Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy C, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth N, Sakrikar D, Perkins M, Harding S, Troske D, Getz G, Karlson EW, Munshi N, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood. 2025.

Sklavenitis-Pistofidis R, Konishi Y, Heilpern-Mallory D, Wu T, Tsakmaklis N, Aranha MP, Hunter ZR, Ali AK, Tsuji J, Haradhvala NJ, Lightbody ED, Towle K, Hevenor L, Romee R, Briercheck EL, Smith EL, Liacos CI, Kastritis E, Dimopoulos MA, Treon SP, Getz G, Ghobrial IM. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia. Nat Commun. 2025.

Nadeem O, Ghobrial IM. Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma. Nat Rev Clin Oncol. 2025.

Ghobrial IM, Chabrun F. Is it time to screen for multiple myeloma? Blood. 2025.

Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Deeper response predicts better outcomes in high-risk smoldering myeloma: results of the I-PRISM phase II clinical trial. Nat Commun. 2025.

2024

Rahmat M, Clement K, Alberge JB, Sklavenitis-Pistofidis R, Kodgule R, Fulco CP, Heilpern-Mallory D, Nilsson K, Dorfman D, Engreitz JM, Getz G, Pinello L, Ryan R, Ghobrial IM. Selective Enhancer Gain of Function Deregulates MYC Expression in Multiple Myeloma. Cancer Research. 2024

Tahri S, Piccinelli S, Su NK, Lampe LM, Dong H, Vergara Cadavid J, Boiarsky R, Papazian N, Lightbody ED, Cao A, Alberge J-B, Ferrari de Andrade L, Rahmat M, Shen Y, Blanco Fernández L, Zabaleta A, Guenther A, Getz G, Sonneveld P, Cupedo T, Wucherpfennig KW, Ghobrial IM, Romee R. Inhibition of MICA and MICB shedding enhances memory-like NK cell-mediated cytotoxicity against multiple myeloma. Blood Advances. 2024.

Cordas dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge J-B, Cliff ERS, Theurich S, von Bergwelt-Baildon M, Ghobrial IM, Subklewe M, Perales M-A, Rejeski K. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature Medicine. 2024.

Lee DJ, O'Donnell EK, Raje N, Panaroni C, Redd R, Ligibel J, Sears DD, Nadeem O, Ghobrial IM, Marinac CR. Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial. JMIR Res Protoc. 2024.

O'Donnell, E. K., Borden, B. A., Ghobrial, I. M. Early Detection of Precursor Diseases of Multiple Myeloma. Hematology/oncology clinics of North America. 2024.

Izzo, F., Myers, R. M., Ganesan, S., Mekerishvili, L., Kottapalli, S., Prieto, T., Eton, E. O., Botella, T., Dunbar, A. J., Bowman, R. L., Sotelo, J., Potenski, C., Mimitou, E. P., Stahl, M., El Ghaity-Beckley, S., Arandela, J., Raviram, R., Choi, D. C., Hoffman, R., Chaligné, R., Abdel-Wahab O, Smibert P, Ghobrial IM, Scandura JM, Marcellino B, Levine RL, Landau, D. A. Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024.

Ghobrial IM, Gormley N, Kumar SK, Mateos M-V, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O’Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery. 2024.

Lee DJ, El-Khoury H, Tramontano AC, Alberge JB, Perry J, Davis MI, Horowitz E, Redd RA, Sakrikar D, Barnidge D, Perkins MC, Harding S, Mucci L, Rebbeck TR, Ghobrial IM, Marinac CR. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population. Blood Adv. 2024.

Earlier Publications

Dutta AK, Alberge JB, Lightbody ED, et al: MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology. Cancer Discov 13:348-363, 2023.

Cowan A, Ferrari F, Freeman SS, et al: Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology. 2023

El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematology. 2022.

Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu C-J, He MX, Braggio E, Fonseca R, Maruvka YE, Guerriero JL, Goldman M, Van Allen EM, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer. 2020.